Semaglutide 2.4 mg is cost-effective for obesity disease management in Japan under retreatment scenarios
Semaglutide 2.4 mg plus diet and exercise reduced the incidence of obesity-related complications including type 2 diabetes, cardiovascular events, obstructive sleep apnea, and gout. The incremental cost-effectiveness ratio was ¥5,300,580/QALY for patients without type 2 diabetes and ¥7,077,984/QALY for patients with type 2 diabetes, with retreatment improving QALY gains.
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
Semaglutide 2.4 mg is cost-effective for obesity disease management in Japan under retreatment scenarios The current body of evidence comprises 1 study. EvidenceHub rates the overall confidence at 32/100 (low).
The Claim
Semaglutide 2.4 mg is cost-effective for obesity disease management in Japan under retreatment scenarios
This conclusion is most relevant to: People with obesity disease in Japan with BMI ≥35 kg/m² and at least 1 obesity-related comorbidity (hypertension, dyslipidemia, or type 2 diabetes), or BMI ≥27 kg/m² with at least 2 obesity-related health disorders.
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸Cost-Effectiveness of Semaglutide 2.4 mg for Obesity Disease Management in Japan: A Lifetime Economic Modeling Study Incorporating Retreatment Scenarios. (Journal of health economics and outcomes research, 2026) —
How It Works
The proposed biological pathway:
- ▸Semaglutide 2.4 mg reduces body weight via GLP-1 receptor agonism
- ▸Weight loss reduces risk factors for obesity-related complications
- ▸Retreatment maintains weight loss and risk reduction over longer periods
- ▸Result: Reduced incidence of type 2 diabetes, cardiovascular events, obstructive sleep apnea, and gout, with improved cost-effectiveness
Who Might Benefit
Evidence fit by population:
- ▸People with obesity disease in Japan with BMI ≥35 kg/m² and at least 1 obesity-related comorbidity (hypertension, dyslipidemia, or type 2 diabetes), or BMI ≥27 kg/m² with at least 2 obesity-related health disorders
Recommended Dose
2.4 mg
Limitations & Caveats
Important context when interpreting this evidence:
- ▸Uncertainty remains around retreatment efficacy and long-term discontinuation
- ▸Modeling study with assumptions that may not reflect real-world clinical practice
Frequently Asked Questions
What is the ICER of semaglutide 2.4 mg for obesity in Japan?▼
The ICER was ¥5,300,580/QALY for patients without type 2 diabetes and ¥7,077,984/QALY for patients with type 2 diabetes.
Does retreatment with semaglutide improve cost-effectiveness?▼
Yes, retreatment significantly improved QALY gains compared with limited or no retreatment, reflecting longer maintenance of treatment benefit.
What obesity-related complications did semaglutide reduce?▼
Semaglutide reduced the incidence of type 2 diabetes, cardiovascular events, obstructive sleep apnea, and gout.
What population was studied in this cost-effectiveness analysis?▼
People with obesity disease in Japan with BMI ≥35 kg/m² and at least 1 comorbidity, or BMI ≥27 kg/m² with at least 2 comorbidities.
References
- 1.Kamada Y, Wada S, Matsuda H, Dai Y. “Cost-Effectiveness of Semaglutide 2.4 mg for Obesity Disease Management in Japan: A Lifetime Economic Modeling Study Incorporating Retreatment Scenarios..” Journal of health economics and outcomes research, 2026. PMID: 42394652 DOI: 10.36469/001c.162614